By Michele Maatouk
Date: Wednesday 19 Aug 2026
(Sharecast News) - Oxford Nanopore Technologies announced a new 2030 revenue target of more than $700m on Wednesday, as it reported a narrowing of its interim losses as revenue ticked higher, driven by strong adoption in EMEAI and across Applied end markets.
No recent information was found.
| Questor :GW Pharmaceuticals | 04-Dec-2014 | Telegraph |
| Questor : Hikma Pharmaceuticals | 13-Mar-2014 | Telegraph |
| Investment Column:BTG | 06-Oct-2011 | The Independent |
| Investment Column:Genus | 09-Sep-2011 | The Independent |
| Questor :Dechra Pharmaceuticals | 08-Sep-2011 | Telegraph |
| Price | 23,289.13 |
| Closing Price Change | 712.93 |
| % Change | 2.50 % |
| 18-Aug-26 Close | 23,289.13 |
You are here: research